MXPA02010458A - Peptido modulador del receptor de trombopoyetina. - Google Patents

Peptido modulador del receptor de trombopoyetina.

Info

Publication number
MXPA02010458A
MXPA02010458A MXPA02010458A MXPA02010458A MXPA02010458A MX PA02010458 A MXPA02010458 A MX PA02010458A MX PA02010458 A MXPA02010458 A MX PA02010458A MX PA02010458 A MXPA02010458 A MX PA02010458A MX PA02010458 A MXPA02010458 A MX PA02010458A
Authority
MX
Mexico
Prior art keywords
receptor modulating
thrombopoietin receptor
modulating peptide
peptide
thrombopoietin
Prior art date
Application number
MXPA02010458A
Other languages
English (en)
Inventor
Tatjana Naranda
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of MXPA02010458A publication Critical patent/MXPA02010458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se relaciona a composiciones farmacéuticas y de diagnostico novedosas que facilitan el tratamiento de trombopoyetina.
MXPA02010458A 2000-04-25 2001-04-23 Peptido modulador del receptor de trombopoyetina. MXPA02010458A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108075A EP1149906A1 (en) 2000-04-25 2000-04-25 Thrombopoietin receptor modulating peptide
PCT/EP2001/004553 WO2001080873A2 (en) 2000-04-25 2001-04-23 Thrombopoietin receptor modulating peptide

Publications (1)

Publication Number Publication Date
MXPA02010458A true MXPA02010458A (es) 2003-06-06

Family

ID=8168467

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010458A MXPA02010458A (es) 2000-04-25 2001-04-23 Peptido modulador del receptor de trombopoyetina.

Country Status (24)

Country Link
US (1) US20030181659A1 (es)
EP (2) EP1149906A1 (es)
JP (1) JP2003530867A (es)
KR (1) KR20030009450A (es)
CN (1) CN1426467A (es)
AR (1) AR030278A1 (es)
AU (2) AU6736601A (es)
BG (1) BG107214A (es)
BR (1) BR0110383A (es)
CA (1) CA2407167A1 (es)
CZ (1) CZ20023517A3 (es)
EA (1) EA006423B1 (es)
EE (1) EE200200610A (es)
GE (1) GEP20063763B (es)
HU (1) HUP0300559A3 (es)
IL (1) IL152204A0 (es)
IS (1) IS6582A (es)
MX (1) MXPA02010458A (es)
NO (1) NO20025114L (es)
PL (1) PL358304A1 (es)
SK (1) SK15262002A3 (es)
WO (1) WO2001080873A2 (es)
YU (1) YU79202A (es)
ZA (1) ZA200208662B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508173A (ja) * 2001-11-07 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ２３２、２０５９、１０６３０、１２８４８、１３８７５、１４３９５、１４６１８、１７６９２または５８８７４を使用する血液障害を処置するための方法および組成物
US7923431B2 (en) * 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
AU2003275077B2 (en) * 2002-09-18 2010-02-04 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
BR0317237A (pt) 2002-12-11 2005-11-01 Ferrosan As Dispositivo para amostragem ou coleta, kit, usos de um dispositivo e de um kit, e, métodos para diminuir a quantidade de um marcador em uma área de amostra, para amostrar de modo qualitativo ou quantitativo uma área quanto ao teor de um marcador e para cultivar microorganismos ou células de mamìferos coletados
NZ544024A (en) * 2003-05-12 2009-06-26 Affymax Inc Novel poly(ethylene glycol) modified compounds and uses thereof
EA010015B1 (ru) * 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
JP2005187435A (ja) * 2003-12-26 2005-07-14 Otsuka Chemical Co Ltd 血小板産生促進組成物
AR054637A1 (es) 2004-01-30 2007-07-11 Ferrosan As Aerosoles y composiciones hemostaticas
EP1786480B1 (en) 2004-07-09 2016-09-21 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
US20090004673A1 (en) * 2006-01-31 2009-01-01 Mitsubishi Kagaku Iatron, Inc. Method for Determining Condition of Disseminated Intravascular Coagulation
JP5569398B2 (ja) 2008-02-29 2014-08-13 フェッローサン メディカル ディバイス エー／エス 止血および／または創傷治癒を促進するための装置
ES2659262T3 (es) * 2011-05-13 2018-03-14 The University Of Tokyo Célula megacariocítica polinucleada y método para la elaboración de plaquetas
CA2865349C (en) 2012-03-06 2021-07-06 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
CA2874290C (en) 2012-06-12 2020-02-25 Ferrosan Medical Devices A/S Dry haemostatic composition
CN105358071B (zh) 2013-06-21 2018-07-31 弗罗桑医疗设备公司 真空膨胀的干组合物和用于保留该干组合物的注射器
CA2928963C (en) 2013-12-11 2020-10-27 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
WO2016058612A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
EP3237041B1 (en) 2014-12-24 2020-01-29 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
BR112017027695A2 (pt) 2015-07-03 2018-09-04 Ferrosan Medical Devices As seringa para retenção e mistura de primeira e segunda substâncias
MX2020011866A (es) 2018-05-09 2021-01-20 Ferrosan Medical Devices As Metodo para preparar una composicion hemostatica.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
WO1996040189A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU2783099A (en) * 1998-02-24 1999-09-06 Receptron, Inc. Receptor derived peptides as modulators of receptor activity

Also Published As

Publication number Publication date
NO20025114L (no) 2002-12-18
SK15262002A3 (sk) 2003-05-02
EA006423B1 (ru) 2005-12-29
US20030181659A1 (en) 2003-09-25
ZA200208662B (en) 2003-10-27
JP2003530867A (ja) 2003-10-21
KR20030009450A (ko) 2003-01-29
EP1149906A1 (en) 2001-10-31
HUP0300559A2 (hu) 2003-06-28
GEP20063763B (en) 2006-03-10
BG107214A (bg) 2003-11-28
AU2001267366B9 (en) 2005-07-14
EE200200610A (et) 2004-08-16
EA200201138A1 (ru) 2003-06-26
IL152204A0 (en) 2003-05-29
PL358304A1 (en) 2004-08-09
EP1278849A2 (en) 2003-01-29
BR0110383A (pt) 2003-01-21
IS6582A (is) 2002-10-14
NO20025114D0 (no) 2002-10-24
CA2407167A1 (en) 2001-11-01
CN1426467A (zh) 2003-06-25
WO2001080873A3 (en) 2002-01-31
YU79202A (sh) 2006-01-16
WO2001080873A2 (en) 2001-11-01
AU6736601A (en) 2001-11-07
AU2001267366B2 (en) 2005-06-30
CZ20023517A3 (cs) 2003-10-15
AR030278A1 (es) 2003-08-20
HUP0300559A3 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
MXPA02006029A (es) Lipopeptidos novedosos como agentes antibacterianos.
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
MXPA02006028A (es) Lipopeptidos novedosos como agentes antibacterianos.
MXPA02006030A (es) Lipopeptidos como agentes antibacterianos.
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
AU3652102A (en) Compounds and their uses
IL151313A0 (en) Lipase containing pharmaceutical compositions
GB0129260D0 (en) Pharmaceutical compositions and their uses
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
GR970300016T1 (en) Lactobacillus strains of human origin, their compositions and uses thereof
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
TNSN04206A1 (en) Novel perindopril salt and pharmaceutical compositions containing same
BR9711306A (pt) Amino a-Úcar citotÄxico e derivados de a-Úcar correlatos de indolopirrolocarbazÄis
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
MXPA03010158A (es) Sulfonamidas.
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
ATE305517T1 (de) Neurotrypsin
AP2001002369A0 (en) Pharmaceutical complex.
MY138502A (en) Novel alkansulfonamides as endothelin antagonists